Martha Raymond Provides an Overview of the Colon Cancer Alliance

Video

Martha Raymond, patient support and outreach director, Colon Cancer Alliance, gives an overview of the advocacy organization and some of the services it provides.

Martha Raymond, Vice President of Programs, Colon Cancer Alliance, gives an overview of the advocacy organization and some of the services it provides.

The Colon Cancer Alliance was founded in 1999 and offers programs in patient support, empowerment and education. The organization also offers a signature patient navigator program. Even though the program just started at the beginning of the year, it has already helped thousands of colorectal cancer patients on their journey.

For more information on the Colon Cancer Alliance, visit http://www.ccalliance.org.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
pancreatic ductal adenocarcinoma

Proactive Management of NALIRIFOX-Related Diarrhea Is Crucial in Metastatic PDAC

Ashley Chan
April 12th 2025
Article

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Image of a vaccine being prepared by a person in a white coat and blue gloves

Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC

Kyle Doherty
Published: March 24th 2025 | Updated: March 24th 2025
Article

Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

The Vitals

Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

Lindsay Fischer
March 1st 2023
Podcast

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

green background with dark blue text indicating FDA and green text indicating approved with a checkmark

FDA Approves Tislelizumab Combo for Advanced ESCC

Ashling Wahner;Kristi Rosa
March 4th 2025
Article

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

Blue image of a person with the esophagus and stomach highlighted in orange

Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma

Bridget Hoyt
February 24th 2025
Article

Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.